Bristol Myers Squibb International Corporation

29 trials Commercial sponsor Merged from 2 name variants

Filter these 29 trials by condition, phase, country and more.

Open in Search →

29 Registered trials

0 Recruiting

31 Completed trials

17 Countries active

36 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase III: 8 Phase II: 8 Phase I/II: 9 Phase I: 1 Phase I (FiH): 2 Other: 1

Oversight events:

6 temporary halts across 3 trials

View oversight register →

100%

31 of 31 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Hepatocellular carcinoma 4 Non-small cell lung cancer 4 Bladder cancer 2 Ovarian cancer 2 Renal cell carcinoma 2 Small cell lung cancer extensive stage 2 Colorectal cancer 2 Gastric cancer 2 Oesophageal adenocarcinoma stage III 1 Peritoneal carcinoma metastatic 1 Renal cell carcinoma stage IV 1 Fallopian tube cancer 1

Top IMPs

NIVOLUMAB 20 IPILIMUMAB 10 RELATLIMAB 6 CISPLATIN 3 NIVOLUMAB, RELATLIMAB 3 PACLITAXEL 3 PEMETREXED 3 CARBOPLATIN 2 FARLETUZUMAB ECTERIBULIN 2 HUMAN IGG1 MONOCLONAL ANTIBODY AGAINST FUCOSYL-GM1 2 REGORAFENIB 2 [89ZR]BMS-986279 1

All trials — page 2

29 total

Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Ended

2023-508067-70-00 Phase I/II 9 countries NIVOLUMAB; NIVOLUMAB, RELATLIMAB; RELATLIMAB
A Phase 3 Study of Nivolumab plus Ipilimumab Versus Sunitinib in untreated Subjects with Advanced or Metastatic Renal Cell Carcinoma (RCC) Ended

2023-504761-23-00 Phase III 13 countries IPILIMUMAB; NIVOLUMAB; SUNITINIB
A Study of Nivolumab and Nivolumab Combinations in Recurrent and Metastatic Colon Cancer Ended

2024-516004-42-01 Phase II 2 countries DARATUMUMAB; IPILIMUMAB; NIVOLUMAB; RELATLIMAB
CheckMate 032:CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 032 Ended

2024-516540-25-00 Phase I/II 1 country IPILIMUMAB; NIVOLUMAB
A Phase II Study of Dasatinib in Children and Adolescents with Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolera… Ended

2024-510784-36-00 Phase I/II 2 countries DASATINIB

Showing 25–29 of 29 trials

← All sponsors A–Z